Ocugen (OCGN) announced its intention to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen: Buy Rating Reiterated as Analyst Highlights Retinal Pipeline Upside and Maintains $12 Price Target
- OCGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocugen completes dosing in GARDian3 trial
- Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
- Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies